A1M Pharma AB has changed its name to Guard Therapeutics International AB

Visit guardtherapeutics.com

Press releases


19 Sep 2019  ·  Regulatory information

A1M Pharma announces positive top-line results from a phase 1a study of ROSgard

A1M Pharma today announced that the results from the initial part of a phase 1a study show that the investigational drug ROSgard™ has a good safety profile and that plasma concentrations that are expected to have a therapeutic effect were achieved. ROSgard is being developed as a potential new treatment for prevention of acute kidney injury in cardiac surgery.

Read more